ATE530176T1 - Verwendung von kaffeesäure und ihren derivaten gegen krebs - Google Patents
Verwendung von kaffeesäure und ihren derivaten gegen krebsInfo
- Publication number
- ATE530176T1 ATE530176T1 AT07826053T AT07826053T ATE530176T1 AT E530176 T1 ATE530176 T1 AT E530176T1 AT 07826053 T AT07826053 T AT 07826053T AT 07826053 T AT07826053 T AT 07826053T AT E530176 T1 ATE530176 T1 AT E530176T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- gleevec
- resistant
- present
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84206006P | 2006-09-01 | 2006-09-01 | |
| PCT/IB2007/053308 WO2008026125A2 (en) | 2006-09-01 | 2007-08-20 | Anti cancer use of caffeic acid and derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE530176T1 true ATE530176T1 (de) | 2011-11-15 |
Family
ID=39015871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07826053T ATE530176T1 (de) | 2006-09-01 | 2007-08-20 | Verwendung von kaffeesäure und ihren derivaten gegen krebs |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100010002A1 (de) |
| EP (1) | EP2061452B1 (de) |
| JP (1) | JP2010502586A (de) |
| AT (1) | ATE530176T1 (de) |
| AU (1) | AU2007290960B2 (de) |
| CA (1) | CA2662126A1 (de) |
| DK (1) | DK2061452T3 (de) |
| ES (1) | ES2376277T3 (de) |
| IL (1) | IL197262A0 (de) |
| PT (1) | PT2061452E (de) |
| TW (1) | TW200812955A (de) |
| WO (1) | WO2008026125A2 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8722665B2 (en) | 2008-11-07 | 2014-05-13 | Council Of Scientific & Industrial Research | Cinnamido-pyrrolo[2,1-C][1,4]benzodiazepines as potential anticancer agents and process for the preparation thereof |
| CN101456890B (zh) * | 2008-12-17 | 2011-02-02 | 中南大学 | 白血病bcr/abl融合基因mRNA的特异性抑制剂 |
| PL2427416T3 (pl) | 2009-05-04 | 2016-09-30 | Podstawione związki aromatyczne i ich zastosowania farmaceutyczne | |
| CN103108867A (zh) | 2010-02-25 | 2013-05-15 | 皮拉马尔企业有限公司 | 噁二唑化合物及其制备和用途 |
| NZ610851A (en) * | 2010-10-27 | 2015-05-29 | Prometic Biosciences Inc | Compounds and compositions for the treatment of cancer |
| WO2013012477A1 (en) * | 2011-05-20 | 2013-01-24 | New York University | Propolis and caffeic acid phenethyl ester and uses thereof |
| US20160194718A1 (en) * | 2013-05-21 | 2016-07-07 | Dana-Farber Cancer Institute, Inc. | Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using Histone H3K27ME3 Biomarkers and Modulators |
| WO2017161093A1 (en) * | 2016-03-17 | 2017-09-21 | Musc Foundation For Research Development | Caffeic acid derivatives and uses thereof |
| US20220370385A1 (en) * | 2019-09-17 | 2022-11-24 | Enzene Biosciences Ltd. | Compositions for use in inhibiting src kinase and treating and preventing associated disorders |
| US11878971B2 (en) | 2020-12-29 | 2024-01-23 | Huscion Co., Ltd. | Piperlongumine-based compound and immuno regulator comprising the same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5216024A (en) * | 1987-07-28 | 1993-06-01 | Baylor College Of Medicine | Cell growth inhibitors and methods of treating cancer and cell proliferative diseases |
| US5008441A (en) * | 1987-08-04 | 1991-04-16 | The Trustees Of Columbia University In The City Of New York | Caffeic acid esters and methods of producing and using same |
| RU2314096C2 (ru) * | 2002-05-31 | 2008-01-10 | Каунсил Оф Сайентифик Энд Индастриал Рисерч | Синергическая фармацевтическая композиция для лечения лейкемии |
| US20040006138A1 (en) * | 2002-07-08 | 2004-01-08 | Council Of Scientific | Pharmaceutical composition useful for treating chronic myeloid leukemia |
| AU2003201062A1 (en) * | 2002-07-08 | 2004-01-23 | Council Of Scientific And Industrial Research | A pharmaceutical composition useful for treating chronic myeloid leukemia |
| US20050282892A1 (en) * | 2002-07-08 | 2005-12-22 | Santu Bandyopadhyay | Pharmaceutical composition useful for treating chronic myeloid leukemia |
| US20070161704A1 (en) * | 2002-07-08 | 2007-07-12 | Council Of Scientific And Industrial Research | Pharmaceutical composition useful for treating chronic myeloid leukemia |
| WO2005099721A2 (en) * | 2004-04-15 | 2005-10-27 | The Regents Of The University Of California | Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof |
| US20060045887A1 (en) | 2004-08-25 | 2006-03-02 | Gavish-Galilee Bio Applications Ltd. | Mushroom extracts having anticancer activity |
-
2007
- 2007-08-20 EP EP07826053A patent/EP2061452B1/de not_active Not-in-force
- 2007-08-20 AT AT07826053T patent/ATE530176T1/de active
- 2007-08-20 US US12/439,587 patent/US20100010002A1/en not_active Abandoned
- 2007-08-20 AU AU2007290960A patent/AU2007290960B2/en not_active Ceased
- 2007-08-20 JP JP2009526219A patent/JP2010502586A/ja active Pending
- 2007-08-20 DK DK07826053.6T patent/DK2061452T3/da active
- 2007-08-20 WO PCT/IB2007/053308 patent/WO2008026125A2/en active Application Filing
- 2007-08-20 PT PT07826053T patent/PT2061452E/pt unknown
- 2007-08-20 ES ES07826053T patent/ES2376277T3/es active Active
- 2007-08-20 CA CA002662126A patent/CA2662126A1/en not_active Abandoned
- 2007-08-22 TW TW096131151A patent/TW200812955A/zh unknown
-
2009
- 2009-02-25 IL IL197262A patent/IL197262A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20100010002A1 (en) | 2010-01-14 |
| PT2061452E (pt) | 2012-01-13 |
| AU2007290960A1 (en) | 2008-03-06 |
| JP2010502586A (ja) | 2010-01-28 |
| ES2376277T3 (es) | 2012-03-12 |
| TW200812955A (en) | 2008-03-16 |
| AU2007290960B2 (en) | 2013-04-18 |
| WO2008026125A2 (en) | 2008-03-06 |
| EP2061452A2 (de) | 2009-05-27 |
| IL197262A0 (en) | 2009-12-24 |
| DK2061452T3 (da) | 2012-02-13 |
| CA2662126A1 (en) | 2008-03-06 |
| EP2061452B1 (de) | 2011-10-26 |
| WO2008026125A3 (en) | 2008-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE530176T1 (de) | Verwendung von kaffeesäure und ihren derivaten gegen krebs | |
| TW200833675A (en) | Nicotinamide derivatives | |
| WO2009155121A3 (en) | Inhibitors of pi3 kinase | |
| EA200601350A1 (ru) | Азотсодержащие гетероциклические производные и их фармацевтические применения | |
| MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
| UA99361C2 (uk) | ТРИАЗИНИ ЯК ІНГІБІТОРИ PІ3-КІНАЗИ І mTOR | |
| MD4582C1 (ro) | Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei | |
| MX2010005435A (es) | Derivados de pirimidina para el tratamiento de asma, epoc, rinitis alergica, conjuntivitis alergica, dermatitis atopica, cancer, hepatitis b, hepatitis c, vih, vph, infecciones bacterianas y dermatosis. | |
| DK2298768T3 (da) | 5-Amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidinderivater og beslægtede forbindelser til behandling af cancer | |
| HK1116161A1 (en) | Substituted amide derivatives as protein kinase inhibitors | |
| MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
| GEP20146125B (en) | Aminopyrimidines as syk inhibitors | |
| MX2009010246A (es) | Derivados de 8-oxi-quinolina como moduladores del receptor bradiquinina b2. | |
| SE0400284D0 (sv) | Novel compounds | |
| WO2008008539A3 (en) | Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor | |
| MXPA06013164A (es) | Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal. | |
| MY148636A (en) | Benzimidazole derivatives | |
| WO2012047017A3 (ko) | 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물 | |
| TW200745066A (en) | Novel PTP1B inhibitors | |
| AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
| UA94622C2 (en) | Kinase innhibitor | |
| UA94606C2 (ru) | Производные тиоксантина, композиция, которая их содержит, и их применение в терапии | |
| EA201001687A1 (ru) | Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 ) | |
| TN2010000038A1 (en) | Organic compounds | |
| MX341341B (es) | Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 2061452 Country of ref document: EP |